HRP20211559T1 - Rnk za liječenje autoimunih bolesti - Google Patents
Rnk za liječenje autoimunih bolesti Download PDFInfo
- Publication number
- HRP20211559T1 HRP20211559T1 HRP20211559TT HRP20211559T HRP20211559T1 HR P20211559 T1 HRP20211559 T1 HR P20211559T1 HR P20211559T T HRP20211559T T HR P20211559TT HR P20211559 T HRP20211559 T HR P20211559T HR P20211559 T1 HRP20211559 T1 HR P20211559T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- use according
- interleukin
- autoimmune disease
- immune system
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 102100021723 Arginase-1 Human genes 0.000 claims 4
- 101710129000 Arginase-1 Proteins 0.000 claims 4
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 claims 4
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 4
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 4
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 4
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 4
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 4
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 claims 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 4
- 102000018822 Retinal Dehydrogenase Human genes 0.000 claims 4
- 108010027691 Retinal dehydrogenase Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 4
- 229940076144 interleukin-10 Drugs 0.000 claims 4
- 229940028885 interleukin-4 Drugs 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 108010066979 Interleukin-27 Proteins 0.000 claims 3
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 101710185498 Acetaldehyde dehydrogenase 1 Proteins 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 2
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 claims 2
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 2
- -1 FAS-IL Proteins 0.000 claims 2
- 102000000795 Galectin 1 Human genes 0.000 claims 2
- 108010001498 Galectin 1 Proteins 0.000 claims 2
- 102100031351 Galectin-9 Human genes 0.000 claims 2
- 101710121810 Galectin-9 Proteins 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102100027718 Semaphorin-4A Human genes 0.000 claims 2
- 101710199422 Semaphorin-4A Proteins 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/058651 WO2018188730A1 (en) | 2017-04-11 | 2017-04-11 | Rna for treatment of autoimmune diseases |
| EP18717580.7A EP3609529B1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
| PCT/EP2018/059188 WO2018189193A1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211559T1 true HRP20211559T1 (hr) | 2022-01-21 |
Family
ID=58632945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211559TT HRP20211559T1 (hr) | 2017-04-11 | 2018-04-10 | Rnk za liječenje autoimunih bolesti |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11701413B2 (enExample) |
| EP (2) | EP3981424A1 (enExample) |
| JP (3) | JP7078641B2 (enExample) |
| KR (2) | KR20240042138A (enExample) |
| CN (2) | CN118161602A (enExample) |
| AU (1) | AU2018253352B2 (enExample) |
| BR (1) | BR112019020667A8 (enExample) |
| CA (1) | CA3059505A1 (enExample) |
| CY (1) | CY1124767T1 (enExample) |
| DK (1) | DK3609529T3 (enExample) |
| ES (1) | ES2893451T3 (enExample) |
| HR (1) | HRP20211559T1 (enExample) |
| HU (1) | HUE056871T2 (enExample) |
| IL (2) | IL269793B (enExample) |
| LT (1) | LT3609529T (enExample) |
| MX (1) | MX2019012144A (enExample) |
| PL (1) | PL3609529T3 (enExample) |
| PT (1) | PT3609529T (enExample) |
| RS (1) | RS62582B1 (enExample) |
| SG (2) | SG10202111163VA (enExample) |
| SI (1) | SI3609529T1 (enExample) |
| SM (1) | SMT202100572T1 (enExample) |
| WO (2) | WO2018188730A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
| EP3880174A2 (en) * | 2018-11-12 | 2021-09-22 | Translate Bio, Inc. | Methods for inducing immune tolerance |
| CN118490818A (zh) * | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN115232825B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的新冠病毒疫苗 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| IL308571A (en) | 2021-05-26 | 2024-01-01 | Imcyse Sa | Methods of treating or preventing autoimmune diseases |
| EP4355875A1 (en) * | 2021-06-14 | 2024-04-24 | 2seventy bio, Inc. | Single stranded rna purification methods |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
| CN113336862B (zh) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
| WO2023030635A1 (en) * | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| CN118369335A (zh) * | 2022-01-06 | 2024-07-19 | 上海吉量医药工程有限公司 | N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
| AU2002952834A0 (en) | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| PL2578685T3 (pl) * | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| ES2769129T3 (es) | 2009-12-07 | 2020-06-24 | Univ Pennsylvania | Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células |
| US9778250B2 (en) * | 2011-05-10 | 2017-10-03 | The Brigham And Women's Hospital, Inc. | Detecting inclusion body myositis |
| US20150044244A1 (en) * | 2011-09-30 | 2015-02-12 | Beijing Advanccine Biotechnology Co. Ltd. | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases |
| DK3421601T3 (da) * | 2011-12-30 | 2020-02-24 | Cellscript Llc | Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt |
| WO2013120498A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| WO2016176330A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| CN106395552B (zh) | 2015-08-03 | 2020-03-17 | 奥的斯电梯公司 | 无绳电梯系统导轨组件 |
| EP3341026B1 (en) * | 2015-08-28 | 2022-01-05 | BioNTech SE | Method for reducing immunogenicity of rna |
| SI3445850T1 (sl) | 2016-04-22 | 2021-12-31 | BioNTech SE | Postopki za zagotavljanje enoverižne RNA |
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
-
2017
- 2017-04-11 WO PCT/EP2017/058651 patent/WO2018188730A1/en not_active Ceased
-
2018
- 2018-04-10 PL PL18717580T patent/PL3609529T3/pl unknown
- 2018-04-10 HU HUE18717580A patent/HUE056871T2/hu unknown
- 2018-04-10 KR KR1020247008874A patent/KR20240042138A/ko not_active Withdrawn
- 2018-04-10 SG SG10202111163VA patent/SG10202111163VA/en unknown
- 2018-04-10 KR KR1020197033154A patent/KR102824942B1/ko active Active
- 2018-04-10 DK DK18717580.7T patent/DK3609529T3/da active
- 2018-04-10 CN CN202410206779.6A patent/CN118161602A/zh active Pending
- 2018-04-10 CN CN201880024391.7A patent/CN110719787B/zh active Active
- 2018-04-10 SG SG11201909520V patent/SG11201909520VA/en unknown
- 2018-04-10 LT LTEPPCT/EP2018/059188T patent/LT3609529T/lt unknown
- 2018-04-10 SM SM20210572T patent/SMT202100572T1/it unknown
- 2018-04-10 HR HRP20211559TT patent/HRP20211559T1/hr unknown
- 2018-04-10 WO PCT/EP2018/059188 patent/WO2018189193A1/en not_active Ceased
- 2018-04-10 PT PT187175807T patent/PT3609529T/pt unknown
- 2018-04-10 RS RS20211224A patent/RS62582B1/sr unknown
- 2018-04-10 US US16/500,005 patent/US11701413B2/en active Active
- 2018-04-10 AU AU2018253352A patent/AU2018253352B2/en active Active
- 2018-04-10 ES ES18717580T patent/ES2893451T3/es active Active
- 2018-04-10 JP JP2019555957A patent/JP7078641B2/ja active Active
- 2018-04-10 EP EP21191317.3A patent/EP3981424A1/en active Pending
- 2018-04-10 BR BR112019020667A patent/BR112019020667A8/pt unknown
- 2018-04-10 MX MX2019012144A patent/MX2019012144A/es unknown
- 2018-04-10 CA CA3059505A patent/CA3059505A1/en active Pending
- 2018-04-10 SI SI201830424T patent/SI3609529T1/sl unknown
- 2018-04-10 EP EP18717580.7A patent/EP3609529B1/en active Active
-
2019
- 2019-10-03 IL IL269793A patent/IL269793B/en unknown
-
2021
- 2021-10-06 CY CY20211100867T patent/CY1124767T1/el unknown
-
2022
- 2022-02-28 IL IL290980A patent/IL290980A/en unknown
- 2022-05-19 JP JP2022082384A patent/JP7444924B2/ja active Active
-
2023
- 2023-06-12 US US18/333,273 patent/US20230330198A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025246A patent/JP2024059794A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | The role of Th17 cells in inflammatory bowel disease and the research progress | |
| Vermillion et al. | Estriol reduces pulmonary immune cell recruitment and inflammation to protect female mice from severe influenza | |
| Tahmasebi et al. | Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2 | |
| Trompette et al. | Dietary fiber confers protection against flu by shaping Ly6c− patrolling monocyte hematopoiesis and CD8+ T cell metabolism | |
| JP2020516658A5 (enExample) | ||
| Zhu et al. | The role of T cells and macrophages in asthma pathogenesis: a new perspective on mutual crosstalk | |
| Puente-Marin et al. | Fish red blood cells modulate immune genes in response to bacterial inclusion bodies made of TNFα and a G-VHSV fragment | |
| Wei et al. | Functional expression and characterization of grass carp IL-10: an essential mediator of TGF-β1 immune regulation in peripheral blood lymphocytes | |
| Lai et al. | M2C polarization by baicalin enhances efferocytosis via upregulation of MERTK receptor | |
| WO2017161387A1 (en) | Compositions of natural extracts and use thereof in methods for preventing or treating diseases | |
| Hua et al. | Immune signaling and autophagy regulation | |
| Liu et al. | NMAAP1 expressed in BCG-activated macrophage promotes M1 macrophage polarization | |
| Bencze et al. | Correlation between type I interferon associated factors and COVID-19 severity | |
| Terán-Cabanillas et al. | Production of interferon α and β, pro-inflammatory cytokines and the expression of suppressor of cytokine signaling (SOCS) in obese subjects infected with influenza A/H1N1 | |
| Yan et al. | Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities | |
| Qian et al. | Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury | |
| Perales-Puchalt et al. | IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment | |
| Mah et al. | The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells | |
| Jeong et al. | Repair of astrocytes, blood vessels, and myelin in the injured brain: possible roles of blood monocytes | |
| Chen et al. | Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1 | |
| Jiang et al. | Transcriptomic profiling of intestinal epithelial cells in response to human, bovine and commercial bovine lactoferrins | |
| Yu et al. | HSF1 promotes CD69+ Treg differentiation to inhibit colitis progression | |
| Henriques-Pons et al. | Pulmonary mesenchymal stem cells in mild cases of COVID-19 are dedicated to proliferation; in severe cases, they control inflammation, make cell dispersion, and tissue regeneration | |
| Zhang et al. | Parthenolide suppresses T helper 17 and alleviates experimental autoimmune encephalomyelitis | |
| Moore et al. | Update in asthma 2009 |